Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 66

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 66
---
 events.

The Company has considered the effect of non-redeemable
ordinary shares that were excluded from weighted average number as they were contingent on the exercise of over-allotment option by the
underwriters. Since the contingency was satisfied, the Company included these shares in the weighted average number as of the beginning
of the interim period to determine the dilutive impact of these shares.

The following table presents a reconciliation
of the numerator and denominator used to compute basic and diluted net income per ordinary share for each class of ordinary shares:

    Three Months Ended June 30,  
    Six Months Ended June 30, 

    2025  
    2025 

    Redeemable shares  
    Non-redeemable shares  
    Redeemable shares  
    Non-redeemable shares 
  
    Basic net income per share: 

    Numerator: 

    Allocation of net income 
    $1,570,460  
    $718,119  
    $2,320,616  
    $1,222,506 
  
    Denominator: 

    Weighted-average shares outstanding 
     23,000,000  
     10,517,143  
     19,110,497  
     10,067,451 
  
    Basic net income per ordinary share 
    $0.07  
    $0.07  
    $0.12  
    $0.12 

    Diluted net income per share: 

    Numerator: 

    Allocation of net income 
    $1,570,460  
    $718,119  
    $2,292,576  
    $1,250,546 
  
    Denominator: 

    Weighted-average shares outstanding 
     23,000,000  
     10,517,143  
     19,110,497  
     10,424,325 
  
    Diluted net income per ordinary share 
    $0.07  
    $0.07  
    $0.12  
    $0.12 

    For The Period from May 23, 2024 (Inception) through June 30, 2024 

    Redeemable  
    Non-Redeemable 
  
    Basic and diluted net loss per share: 

    Numerator: